Is CRISPR Therapeutics (CRSP) Near Fair Value With $2.4B In Cash?

CRISPR Therapeutics stock has given up around 60% over the past five years, yet recent checks suggest it now sits closer to a fair, middle-of-the-road valuation rather than being clearly cheap or clearly expensive.

• Over five years the share price has declined about 60%, which sets expectations low and puts more focus on whether the current valuation fairly reflects the company’s prospects.
• Strong cash reserves of about US$2.4b and a growing gene editing pipeline can support long development timelines, while the pace and scale at which its therapies translate into self-sustaining cash flows remains a key uncertainty for valuation.
• With a value score of 3 out of 6, CRISPR Therapeutics screens as a mixed picture rather than a clear bargain or a clear overvaluation on the broader checks.

The issue now is whether the current price around US$51.37 offers enough compensation for those risks after a long period of weak returns.

Find out why CRISPR Therapeutics' -6.8% return over the last year is lagging behind its peers.

Where Does CRISPR Therapeutics Sit on Book Value?

P/B is often a clear quick check for a business like CRISPR Therapeutics that is still working toward steady profitability, because it anchors the stock price to the current equity base rather than earnings.

CRISPR Therapeutics trades on a P/B of about 2.8x, which sits slightly above the biotech industry average of roughly 2.7x but well below a broader peer group around 9.5x. That places the stock in a middle ground where the market is not paying a large premium to industry book values, yet also is not assigning it the richer multiples seen across some peers in the gene editing space.

Because CRISPR Therapeutics carries about US$2.4b of cash and securities and is already generating commercial revenue, this mid range P/B indicates the current price is roughly in line with what investors are paying for similar biotech balance sheets. It also leaves scope for differing views on how its pipeline might translate into returns over time.

Overall, the current P/B multiple indicates CRISPR Therapeutics is trading at a level that is broadly in line with typical biotech book values.

See what the numbers say about this price — find out in our valuation breakdown.

The CRISPR Therapeutics Narrative: What Would Justify Today's Price?

Simply Wall St Narratives for CRISPR Therapeutics sit alongside the valuation checks above and spell out, in plain terms, what would need to happen with CRISPR Therapeutics' growth, margins and earnings for the stock to be worth materially more or less than it is today. They are available on the company’s Community page. Where a single ratio or model gives you one output, these narratives unpack the future that number relies on so you can see what to watch over time.

If you have a clear view on whether CRISPR Therapeutics' cash position and gene editing work, including developments like the experimental CRISPR based "DNA shredder", can justify today's price, consider sharing a Narrative in the Simply Wall St community to set out your numbers and assumptions.

It is a chance to add your voice, present a structured case on CRISPR Therapeutics' outlook, and see how it holds up as new data and results come through.

Do you think there's more to the story for CRISPR Therapeutics? Head over to our Community to see what others are saying!

The Bottom Line

CRISPR Therapeutics now screens as about right on market multiples, with its P/B ratio sitting close to broader biotech levels rather than flagging a clear opportunity or clear excess. That leaves the valuation finely balanced. The real question is whether the company can turn its gene editing pipeline and cash position into durable, self-funding cash flows. For readers, the key swing factor is confidence in how quickly and reliably CRISPR Therapeutics can convert today’s projects into commercial therapies that justify holding the stock at something like its current multiple.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com